+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Kaposi Sarcoma Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896233
  • Report
  • January 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence


  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Pfizer Inc.
  • MORE
Market Overview

The growing prevalence of the Kaposi Sarcoma and the rising number of patients undergoing organ transplantation procedures as patients undergoing organ transplantations are more susceptible for Kaposi sarcoma, are the major factor attributing the growth of the Kaposi sarcoma market. According to Global Observatory On Donation And Transplantation, 1,39,024 organs were transplanted globally in 2017. Where 90,306 (Kidney), 32,348 (Liver), 7,881 (Heart), 6,084 (Lung), 2,243 (Pancreas), 162 (Small Bowel) transplantations took place. Moreover, the promising number of pipeline studies, growing incidence of HIV-associated Kaposi sarcoma is also a major factor driving Kaposi sarcoma market. However, a shortage in supply of drugs due to a wide demand-supply gap, lack of awareness about this type of cancer, high cost of the treatment and diagnosis of Kaposi sarcoma will impede the growth of the market studied globally.

Scope of the Report

As per the American Cancer Society, “Kaposi sarcoma (KS) is cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but these tumors can also develop in other parts of the body, such as in the lymph nodes (bean-sized collections of immune cells throughout the body), the lungs, or digestive tract”. KS is caused by a virus called human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpes virus (KSHV).

Key Market Trends

Highly Active Antiretroviral Therapy (HAART) Segment Holds Significant Market Share
  • Kaposi sarcoma (KS) is common cancer associated with the HIV infection and it is considered as an AIDS-defining condition by the US Centers for Disease Control Guidelines.
  • Numerous advancements in the treatment of AIDS-related Kaposi sarcoma have been attained over the last few years, but the introduction of highly active antiretroviral therapy (HAART) has declined the incidences of AIDS-defining illnesses, including KS.
  • For individuals with Epidemic (AIDS-associated) Kaposi sarcoma, antiretroviral treatment for HIV/AIDS is generally used prior to any other therapies for treating the tumor and to reduce the symptoms. HAART might be given as individual therapy or in the combination with chemotherapy depending on the spread of the disease and the patient’s symptoms.
  • Seldom, HAART might worsen the condition of the Kaposi sarcoma and the pre-existing infections which leads to a condition called immune reconstitution inflammatory syndrome (IRIS).
North America holds the Largest Market Share in Global Kaposi Sarcoma Market

North America region holds a major market share in the Kaposi treatment market globally. Major factors contributing to this position are the increasing number of product approvals, the presence of many numbers of market players in the market, a high number of R&D initiatives undergoing the treatment and the diagnosis of the Kaposi sarcoma. Additionally, the increasing prevalence of Kaposi sarcoma and HIV is also bolstering the market growth in the region. For instance, According to the American Cancer Society's (ACS) publication, about 1 in 200 transplant recipients in the United States develops Kaposi sarcoma.

Competitive Landscape

Kaposi Sarcoma market has rapidly progressed over the last few years. Industry observed significant changes in adopting market strategies such as product developments, mergers, and acquisitions in recent years. For instance, in May 2019, The USFDA granted breakthrough therapy designation to Celgene’s pomalidomide (Pomalyst) for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Pfizer Inc.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Incidence of HIV-Associated Kaposi Sarcoma
4.2.2 Rising Number of Patients Undergoing Organ Transplantation Procedures
4.3 Market Restraints
4.3.1 High Cost Of The Treatment And Diagnosis Of Kaposi Sarcoma
4.3.2 Shortage In Supply Of Drugs Due To Wide Demand-Supply Gap
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Epidemic (AIDS-associated) Kaposi sarcoma
5.1.2 Classic (Mediterranean) Kaposi sarcoma
5.1.3 Endemic (African) Kaposi sarcoma
5.1.4 Latrogenic (transplant-related) Kaposi sarcoma
5.2 By Product
5.2.1 By Diagnostics Biopsy Bronchoscopy Gastrointestinal endoscopy Others
5.2.2 By Treatment Highly Active Antiretroviral Therapy (HAART) Radiation Therapy Chemotherapy Immunotherapy Others
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Merck & Co., Inc.
6.1.2 Celgene Corporation
6.1.3 Eli Lilly and Company
6.1.4 Navidea Biopharmaceuticals, Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Bristol-Myers Squibb
6.1.7 Pfizer Inc.

Note: Product cover images may vary from those shown
  • Merck & Co., Inc.
  • Celgene Corporation
  • Eli Lilly and Company
  • Navidea Biopharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb
  • Pfizer Inc.
Note: Product cover images may vary from those shown